Abstract: The present invention relates to refined prognostic clinical tools, methods, and kits for the evaluation of risk and treatment of distant recurrence in ER+/HER2? breast cancer patients.

Abstract: An inhibitor of polycomb for use in the treatment and/or prevention of an endothelial to mesenchymal transition associated pathology is provided. Preferably, the inhibitor inhibits at least one polycomb repressive complex. The present invention also relates to a pharmaceutical composition having an inhibitor of polycomb for use in the treatment and/or prevention of an endothelial to mesenchymal transition associated pathology and to a method to identify an inhibitor of polycomb.

Abstract: A cell compression device having a main body including a central internal cavity with a symmetry longitudinal axis and a lower opening aligned with the axis, and a deformable membrane having a piston attached thereto is disclosed. The membrane is clamped to the main body at the lower opening to close the central internal cavity forming a variable pressure chamber. The attached piston is located outside the variable pressure chamber and the membrane being clamped to the main body in correspondence with clamping points. When the deformable membrane is clamped to the main body, the membrane is in a relaxed configuration, wherein the distance of two opposing clamping points is lower than the length of the membrane between the two opposing clamping points, and a symmetry longitudinal axis of the main portion of the piston coincides with the symmetry longitudinal axis of the central internal cavity.